Wall Street brokerages forecast that Retrophin, Inc. (NASDAQ:RTRX) will report $40.82 million in sales for the current quarter, Zacks reports. Two analysts have issued estimates for Retrophin’s earnings, with the highest sales estimate coming in at $42.50 million and the lowest estimate coming in at $39.14 million. Retrophin posted sales of $33.95 million during the same quarter last year, which would indicate a positive year-over-year growth rate of 20.2%. The company is expected to report its next earnings results after the market closes on Tuesday, November 7th.

On average, analysts expect that Retrophin will report full year sales of $40.82 million for the current year, with estimates ranging from $152.69 million to $154.80 million. For the next fiscal year, analysts forecast that the company will post sales of $184.40 million per share, with estimates ranging from $184.19 million to $184.60 million. Zacks Investment Research’s sales averages are an average based on a survey of sell-side analysts that cover Retrophin.

Retrophin (NASDAQ:RTRX) last posted its earnings results on Wednesday, August 9th. The biopharmaceutical company reported ($0.34) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.24) by ($0.10). Retrophin had a negative return on equity of 7.31% and a negative net margin of 48.74%. The firm had revenue of $38.80 million for the quarter, compared to analyst estimates of $37.36 million. During the same period in the prior year, the business posted $0.07 EPS. The firm’s quarterly revenue was up 16.5% compared to the same quarter last year.

A number of research analysts have issued reports on the company. BMO Capital Markets restated a “buy” rating and issued a $44.00 price objective on shares of Retrophin in a research note on Friday, October 6th. BidaskClub upgraded Retrophin from a “buy” rating to a “strong-buy” rating in a research note on Thursday, August 24th. Finally, ValuEngine upgraded Retrophin from a “sell” rating to a “hold” rating in a research note on Friday, August 4th. One analyst has rated the stock with a hold rating, three have given a buy rating and one has given a strong buy rating to the stock. Retrophin currently has an average rating of “Buy” and an average target price of $36.00.

In other news, COO Neil F. Mcfarlane sold 1,378 shares of the stock in a transaction on Wednesday, August 16th. The stock was sold at an average price of $22.50, for a total transaction of $31,005.00. Following the completion of the transaction, the chief operating officer now owns 13,622 shares in the company, valued at approximately $306,495. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 2.41% of the stock is currently owned by corporate insiders.

Hedge funds have recently bought and sold shares of the company. Nationwide Fund Advisors grew its stake in shares of Retrophin by 14.6% during the 2nd quarter. Nationwide Fund Advisors now owns 59,424 shares of the biopharmaceutical company’s stock worth $1,152,000 after acquiring an additional 7,583 shares during the period. Prudential Financial Inc. bought a new position in shares of Retrophin during the 2nd quarter worth $775,000. State of Wisconsin Investment Board bought a new position in shares of Retrophin during the 2nd quarter worth $543,000. Emory University bought a new position in shares of Retrophin during the 2nd quarter worth $1,767,000. Finally, Schwab Charles Investment Management Inc. grew its stake in shares of Retrophin by 35.7% during the 2nd quarter. Schwab Charles Investment Management Inc. now owns 277,688 shares of the biopharmaceutical company’s stock worth $5,385,000 after acquiring an additional 73,067 shares during the period.

TRADEMARK VIOLATION WARNING: This story was originally posted by American Banking News and is the sole property of of American Banking News. If you are reading this story on another website, it was illegally copied and reposted in violation of US and international copyright and trademark laws. The original version of this story can be read at https://www.americanbankingnews.com/2017/10/28/40-82-million-in-sales-expected-for-retrophin-inc-rtrx-this-quarter-3.html.

Shares of Retrophin (RTRX) opened at 24.41 on Friday. Retrophin has a 12-month low of $15.55 and a 12-month high of $25.44. The firm’s market cap is $936.98 million. The stock’s 50 day moving average price is $24.05 and its 200-day moving average price is $20.70.

About Retrophin

Retrophin, Inc is a biopharmaceutical company. The Company is focused on the development, acquisition and commercialization of therapies for the treatment of serious, catastrophic or rare diseases. The Company sells three products, including Chenodal (chenodeoxycholic acid), Cholbam (cholic acid) and Thiola (tiopronin).

Get a free copy of the Zacks research report on Retrophin (RTRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Retrophin (NASDAQ:RTRX)

Receive News & Ratings for Retrophin Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Retrophin Inc. and related companies with MarketBeat.com's FREE daily email newsletter.